Abstract:SESSION TITLE: Diffuse Lung Disease Posters 5 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a highly fatal lung disease of unknown cause with a median survival time of only 3-5 years. Current evidence manifests differentiation of lung fibroblasts into αSMA-positive myofibroblasts is important in the progress of IPF. However, few biomarkers reflecting the fibrotic process have been identified. In this study, we aim to explore whether LTBP2 is a new potential biomarker for predicting the progression and diagnosis of IPF, and which cell population may be the main cells for LTBP2 highly expressed to promote the progression of IPF disease. METHODS: The microarray data of GSE17978 and GSE53845 datasets were downloaded from the GEO database to analyze differentially expressed genes. Single-cell transcriptomic data of IPF patients and healthy donors were selected from GSE122960. IPF and healthy donor lung tissue samples were acquired from the First Affiliated Hospital of Zhengzhou University. This study was approved by Ethical Committee for Scientific Research and Clinical Trials of the First Affiliated Hospital of Zhengzhou University. The isolated lung tissue was placed in 10% formalin within half an hour and subsequently embedded in paraffin. Paraffin sections were used for HE and Masson staining to find fibroblast foci. Immunohistochemical techniques were used to detect the expression of LTBP2 in fibroblasts/myofibroblasts in the fibroblast foci of IPF lung tissues. Starving MRC-5 cells and CCC-HPF-1 cells in DMEM medium without fetal bovine serum for 12 hours, respectively, and then adding TGF-β1 at a concentration of 10 ng/ml. After 48 hours of stimulation, a fibrotic phenotype of fibroblasts was constructed. RESULTS: Utilizing GSE17978 and GSE53845 data, we found that the mRNA level of LTBP2 in IPF lung tissue was significantly higher than that in healthy lung tissue. In GSE122920 data, 14 major cell populations were clustered and identified based on screening out the expression of canonical cell markers. LTBP2 was strongly expressed in the fibroblast population. Additionally, LTBP2 was highly expressed in fibroblasts from IPF while fibroblasts from healthy donors rarely expressed LTBP2. Next, immunohistochemical analysis showed that LTBP2 was extensively positive in IPF lung tissue, and LTBP2 was strongly positive in fibroblasts/myofibroblasts in the fibroblast foci. Using serum-free DMEM containing 10 ng/ml of TGF-β1 to culture MRC-5 and CCC-HPF-1 cells respectively, the mRNA level of LTBP2 increased in a time-dependent manner, reaching the peak at 48 hours. CONCLUSIONS: In conclusion, we developed a validated and reproducible IRG-based prognostic signature that should be helpful for the personalized management of patients with IPF. CLINICAL IMPLICATIONS: Providing a new direction for targeted treatment of IPF. DISCLOSURES: No relevant relationships by Shanshan Chen No relevant relationships by Zemin Fang No relevant relationships by Liang Guo No relevant relationships by Chun Huang No relevant relationships by Hongxia Jia No relevant relationships by Hui Li No relevant relationships by Chunya Lu No relevant relationships by Lingxiao Qiu No relevant relationships by Wenjuan Wu No relevant relationships by Zhi Xu No relevant relationships by Xinye Zhang No relevant relationships by Guojun Zhang No relevant relationships by Huasi Zhao

lncITPF Promotes Pulmonary Fibrosis by Targeting hnRNP-L Depending on Its Host Gene ITGBL1

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF

LncRNA CTD-2528L19.6 prevents the progression of IPF by alleviating fibroblast activation

LncRNA Hoxaas3 Promotes Lung Fibroblast Activation and Fibrosis by Targeting Mir-450B-5p to Regulate Runx1.

The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis

ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis

Interaction of Long Noncoding RNAs and Micrornas in the Pathogenesis of Idiopathic Pulmonary Fibrosis.

The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1

LncRNA PFAR Contributes to Fibrogenesis in Lung Fibroblasts Through Competitively Binding to Mir-15A.

Hypoxia and Transforming Growth Factor 1 Regulation of Long Non-Coding RNA Transcriptomes in Human Pulmonary Fibroblasts

Astaxanthin attenuates pulmonary fibrosis through lncITPF and mitochondria‐mediated signal pathways

Long non-coding RNA H19 deficiency ameliorates bleomycin-induced pulmonary inflammation and fibrosis

MiR-338* Suppresses Fibrotic Pathogenesis in Pulmonary Fibrosis Through Targeting LPA1.

LncRNA TUG1 promotes pulmonary fibrosis progression via up-regulating CDC27 and activating PI3K/Akt/mTOR pathway

Ltbp2 is a potential biomarker reflecting the fibrotic progression

Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis

TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation

MiR-5100 Targets TOB2 to Drive Epithelial-Mesenchymal Transition Associated with Activating Smad2/3 in Lung Epithelial Cells.

LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation

LncRNA FEZF1-AS1 promotes pulmonary fibrosis via up-regulating EZH2 and targeting miR-200c-3p to regulate the ZEB1 pathway